Nuvation Bio Inc (NYSE: NUVB) on Friday, plunged -8.36% from the previous trading day, before settling in for the closing price of $2.87. Within the past 52 weeks, NUVB’s price has moved between $1.21 and $4.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -517.71%. With a float of $229.11 million, this company’s outstanding shares have now reached $337.57 million.
Let’s look at the performance matrix of the company that is accounted for 51 employees. In terms of profitability, gross margin is -32.69%, operating margin of -5541.88%, and the pretax margin is -21940.68%.
Nuvation Bio Inc (NUVB) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Nuvation Bio Inc is 32.13%, while institutional ownership is 43.46%. The most recent insider transaction that took place on Nov 11 ’24, was worth 162,883. In this transaction CEO, ANHEART THERAPEUTICS LTD. of this company sold 56,361 shares at a rate of $2.89, taking the stock ownership to the 3,866,228 shares. Before that another transaction happened on Oct 08 ’24, when Company’s Director bought 100,000 for $2.20, making the entire transaction worth $220,000. This insider now owns 100,000 shares in total.
Nuvation Bio Inc (NUVB) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.05 earnings per share (EPS) for the period topping the consensus outlook (set at -0.08) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -517.71% per share during the next fiscal year.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Nuvation Bio Inc (NUVB) is currently performing well based on its current performance indicators. A quick ratio of 9.57 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 376.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Nuvation Bio Inc (NYSE: NUVB) saw its 5-day average volume 2.95 million, a positive change from its year-to-date volume of 1.49 million. As of the previous 9 days, the stock’s Stochastic %D was 70.74%. Additionally, its Average True Range was 0.19.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 31.98%, which indicates a significant decrease from 50.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.44% in the past 14 days, which was higher than the 74.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.55, while its 200-day Moving Average is $2.76. Nevertheless, the first resistance level for the watch stands at $2.83 in the near term. At $3.03, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.16. If the price goes on to break the first support level at $2.50, it is likely to go to the next support level at $2.37. The third support level lies at $2.17 if the price breaches the second support level.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
Market capitalization of the company is 813.56 million based on 249,245K outstanding shares. Right now, sales total 0 K and income totals -75,800 K. The company made 730 K in profit during its latest quarter, and -41,210 K in sales during its previous quarter.
